, Tracking Stock Market Picks
Enter Symbol:
MiMedx Group, Inc. (MDXG) [hlAlert]

up 129.53 %

MiMedx Group, Inc. (MDXG) rated Outperform with price target $5 by Northland Securities

Posted on: Friday,  Jan 4, 2013  8:25 AM ET by Northland Securities

Northland Securities rated Outperform MiMedx Group, Inc. (NASDAQ: MDXG) on 01/04/2013, when the stock price was $4.13. Since
then, MiMedx Group, Inc. has gained 129.54% as of 01/12/2016's recent price of $9.48.
If you would have followed this Northland Securities's recommendation on MDXG, you would have gained 129.53% of your investment in 1103 days.

MiMedx Group, Inc. is a development-stage company. The Company?s business is conducted by its three divisions: MiMedx, Inc. (MiMedx), SpineMedica, LLC (SpineMedica) and Level Orthopedics. The Company operates in one business segment, musculoskeletal products, which includes the design, manufacture and marketing of products for three major market categories: Orthopedic- Sports Medicine, with soft-tissue reconstructive products focused on repairing tendons and ligaments, Orthopedics-Spine, including products, such as its Paradis Vaso Shield, which is indicated for use as a cover for vessels following anterior vertebral surgery, and Orthopedic-Extremities, with implants for fracture fixation in the upper extremities (hand, wrist, elbow and shoulder). In October 2009, the Company sold the assets of LeveL Orthopedics.

Our equity research effort attempts to identify high potential small-cap investment ideas. We offer traditional sell-side research services with a particular focus on unearthing information that either supports or challenges our investment thesis. We strive to continuously provide our institutional client base with timely and insightful thinking.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/4/2013 8:25 AM Buy
4.13 5.00
as of 12/13/2013
1 Week up  11.31 %
1 Month up  39.24 %
3 Months up  93.28 %
1 YTD up  88.13 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy